Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma Interventions: Drug: Carboplatin; Biological: Pembrolizumab Sponsors: University of Washington; National Cancer Institute (NCI); United States Department of Defense Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Fallopian Tube Cancer | Ovarian Cancer | Ovaries | Peritoneal Cancer | Research